BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37501500)

  • 1. High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
    Caponio VCA; Zhurakivska K; Mascitti M; Togni L; Spirito F; Cirillo N; Lo Muzio L; Troiano G
    Oral Dis; 2024 May; 30(4):2018-2026. PubMed ID: 37501500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
    Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L
    Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
    Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
    Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
    Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
    Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
    Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
    Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
    Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 16. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
    N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma.
    Gleber-Netto FO; Neskey D; Costa AFM; Kataria P; Rao X; Wang J; Kowalski LP; Pickering CR; Dias-Neto E; Myers JN
    Cancer; 2020 Oct; 126(20):4498-4510. PubMed ID: 32797678
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cao CH; Liu R; Lin XR; Luo JQ; Cao LJ; Zhang QJ; Lin SR; Geng L; Sun ZY; Ye SK; Yu ZY; Shi Y; Xia X
    Int J Biol Sci; 2021; 17(7):1744-1756. PubMed ID: 33994859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
    Omura G; Ando M; Ebihara Y; Saito Y; Kobayashi K; Fukuoka O; Akashi K; Yoshida M; Asakage T; Yamasoba T
    BMC Cancer; 2017 Dec; 17(1):898. PubMed ID: 29282038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.